These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8521733)

  • 1. Verapamil-tobramycin synergy in Pseudomonas cepacia but not Pseudomonas aeruginosa in vitro.
    Cohn RC; Rudzienski L; Putnam RW
    Chemotherapy; 1995; 41(5):330-3. PubMed ID: 8521733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
    Treerat P; Widmer F; Middleton PG; Iredell J; George AM
    FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis.
    Cohn RC; Jacobs M; Aronoff SC
    Antimicrob Agents Chemother; 1988 Mar; 32(3):395-6. PubMed ID: 3364958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substituted amines synergistic with tobramycin against Burkholderia cepacia in vitro.
    Cohn RC; Rudzienski L
    Chemotherapy; 1997; 43(2):100-7. PubMed ID: 9084918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.
    McGhee P; Clark C; Credito K; Beachel L; Pankuch GA; Appelbaum PC; Kosowska-Shick K
    Antimicrob Agents Chemother; 2011 May; 55(5):2417-9. PubMed ID: 21343445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
    Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM; Brown SD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T; Petrova G; Mitov I
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa.
    Zuravleff JJ; Yu VL; Yee RB
    J Lab Clin Med; 1983 Jun; 101(6):896-902. PubMed ID: 6406628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of sodium on amiloride-tobramycin synergy in Pseudomonas cepacia.
    Cohn RC; Aronoff SC
    J Lab Clin Med; 1989 Dec; 114(6):724-7. PubMed ID: 2592859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro.
    Tunney MM; Scott EM
    J Microbiol Methods; 2004 Apr; 57(1):107-14. PubMed ID: 15003693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex.
    Veloira WG; Domenico P; LiPuma JJ; Davis JM; Gurzenda E; Kazzaz JA
    J Antimicrob Chemother; 2003 Dec; 52(6):915-9. PubMed ID: 14585856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1403-5. PubMed ID: 3118798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin.
    Halwani M; Blomme S; Suntres ZE; Alipour M; Azghani AO; Kumar A; Omri A
    Int J Pharm; 2008 Jun; 358(1-2):278-84. PubMed ID: 18448284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
    Saiman L; Chen Y; Gabriel PS; Knirsch C
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1105-7. PubMed ID: 11897598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.
    Livermore DM; Mushtaq S; Ge Y; Warner M
    Int J Antimicrob Agents; 2009 Nov; 34(5):402-6. PubMed ID: 19428220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia.
    Kumar A; Hay MB; Maier GA; Dyke JW
    J Antimicrob Chemother; 1992 Nov; 30(5):597-602. PubMed ID: 1283606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.
    Narayanaswamy VP; Giatpaiboon S; Baker SM; Wiesmann WP; LiPuma JJ; Townsend SM
    PLoS One; 2017; 12(6):e0179776. PubMed ID: 28662114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.